RenovoRx, Inc. 8-K

What Happened
RenovoRx, Inc. (RNXT) filed an 8-K reporting that on February 3, 2026 Ronald B. Kocak voluntarily resigned as the Company’s Principal Accounting Officer effective at close of business that day. Kocak remains Vice President and Controller and will keep his current 2026 salary. On February 4, 2026 the Board appointed Mark Voll as Chief Financial Officer; Voll will serve as the Company’s Principal Financial and Accounting Officer for SEC and regulatory purposes.

Key Details

• Kocak’s resignation was voluntary and is not considered a “Good Reason” or “Qualified Termination” under his change-in-control/severance agreement.
• Mark Voll’s appointment effective February 4, 2026; he is a 72‑year‑old finance executive with 30+ years’ experience, including multiple CFO roles and experience leading IPOs.
• Voll will serve as an independent contractor under a Consulting Agreement payable $250 per hour (50% cash, 50% in restricted stock units subject to Compensation Committee approval).
• Voll is to receive an initial grant of 60,000 unvested restricted stock units (subject to the Company’s 2021 Omnibus Equity Incentive Plan and Compensation Committee approval); either party may terminate the consulting arrangement with 30 days’ written notice. A press release announcing the appointment was issued Feb 5, 2026.

Why It Matters
A change in the company’s principal financial and accounting officer can affect financial reporting, investor communications, and the audit relationship. Voll’s consulting agreement ties part of his pay to restricted stock units, which could have future share‑based compensation implications if approved and vested. Kocak’s retention as VP and Controller and continuation of his 2026 salary suggests continuity in day-to-day accounting operations during the transition.